Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Prestwick3_000574

    Client Email Product

    Prestwick3_000574

    APIs // Active Pharmaceutical Ingredients

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    19
    US DMFs Filed

    US DMFs Filed

    10
    CEP/COS Certifications

    CEP/COS Certifications

    5
    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    4
    Other Suppliers

    Other Suppliers

    6
    API REF. PRICE (USD / KG)
    3,541

    API Market Place

    1
    INTERMEDIATES
    1
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    14
    Europe

    Europe

    7
    Canada

    Canada

    1
    Australia

    Australia

    0

    South Africa

    South Africa

    2
    Uploaded Dossiers

    Uploaded Dossiers

    19
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    0

    Annual Reports

    0

    FDF Market Place

    3
    EXCIPIENTS
    31
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    13
    REF STANDARD

    EDQM

    3

    USP

    3

    JP

    0

    Other Listed Suppliers

    3
    SERVICES

    0

    Full View ScreenFull Screen View
    Seagen Eyes a Key Frontline Indication for Top-Seller Adcetris
    Seagen Eyes a Key Frontline Indication for Top-Seller Adcetris

    https://www.biospace.com/article/seagen-eyes-a-key-frontline-indication-for-adcetris/

    Kate Goodwin BIOSPACE
    13 Dec 2022
    Share Share
    Teva's troubled plant seen to create injectable drug shortages
    Teva's troubled plant seen to create injectable drug shortages

    https://www.fiercepharma.com/manufacturing/tevas-halt-production-troubled-plant-seen-create-shortages-range-injectables

    Joseph Keenan FIERCEPHARMA
    24 May 2022
    Share Share
    ADCETRIS Combination Significantly Improves Overall Survival in Hodgkin Lymphoma
    ADCETRIS Combination Significantly Improves Overall Survival in Hodgkin Lymphoma

    https://www.businesswire.com/news/home/20220203005330/en

    BUSINESSWIRE
    03 Feb 2022
    Share Share
    Seagen Announces Preliminary Results from Phase 2 Trial of ADCETRIS
    Seagen Announces Preliminary Results from Phase 2 Trial of ADCETRIS

    https://www.businesswire.com/news/home/20211212005054/en

    BUSINESSWIRE
    12 Dec 2021
    Share Share
    Enforcement Report - Week of March 3, 2021
    Enforcement Report - Week of March 3, 2021

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-3-2021-1614760051.pdf

    FDA
    03 Mar 2021
    Share Share
    European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD
    European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD

    https://www.businesswire.com/news/home/20190211005381/en/European-Commission-Approves-ADCETRIS%C2%AE-brentuximab-vedotin-AVD

    BUSINESSWIRE
    11 Feb 2019
    Share Share
    US FDA accepts sBLA & grants priority review status for Adcetris
    US FDA accepts sBLA & grants priority review status for Adcetris

    http://www.pharmabiz.com/NewsDetails.aspx?aid=106519&sid=2

    PHARMABIZ
    04 Jan 2018
    Share Share
    Will subgroup stumbles for Adcetris hurt its sales potential?
    Will subgroup stumbles for Adcetris hurt its sales potential?

    https://www.fiercepharma.com/marketing/ash-subgroup-stumbles-for-seattle-genetics-adcetris-could-hurt-its-sales-potential

    Carly Helfand FIERCE PHARMA
    12 Dec 2017
    Share Share
    FDA approves Eisai's drug Halaven for type of soft tissue cancer
    FDA approves Eisai's drug Halaven for type of soft tissue cancer

    http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm483795.htm

    FDA
    28 Jan 2016
    Share Share
    Array's skin cancer drug succeeds in late-stage study
    Array's skin cancer drug succeeds in late-stage study

    http://www.reuters.com/article/us-array-biopharma-study-idUSKBN0TZ1IU20151216

    Natalie Grover REUTERS
    17 Dec 2015
    Share Share
    CytRx Announces Completion of Enrollment in Pivotal Global Ph3 Trial Ahead
    CytRx Announces Completion of Enrollment in Pivotal Global Ph3 Trial Ahead

    http://www.prnewswire.com/news-releases/cytrx-announces-the-completion-of-enrollment-in-pivotal-global-phase-3-trial-ahead-of-schedule-300185476.html

    PR NEWS WIRE
    01 Dec 2015
    Share Share
    Attix Pharmaceuticals Recalls Hundreds of APIs From the U.S.
    Attix Pharmaceuticals Recalls Hundreds of APIs From the U.S.

    http://www.fiercepharmamanufacturing.com/story/attix-pharmaceuticals-recalls-hundreds-apis-us/2015-04-30

    Eric Palmer FIERCE PHARMA MFG
    02 May 2015
    Share Share
    Hospira Inc., Ongoing Class III recall of Dacarbazine, Injection, USP, 200mg, vials packaged in individual cartons, Rx only, Manufactured by Hospira Australia 1 Lexia Place, Mulgrave, Victoria Australia 3170. NDC 61703-327-22. because of Discoloration: Reconstituted solution may appear pink instead of colorless to pale yellow when stored per the labeled conditions.
    Hospira Inc., Ongoing Class III recall of Dacarbazine, Injection, USP, 200mg, vials packaged in individual cartons, Rx only, Manufactured by Hospira Australia 1 Lexia Place, Mulgrave, Victoria Australia 3170. NDC 61703-327-22. because of Discoloration: Reconstituted solution may appear pink instead of colorless to pale yellow when stored per the labeled conditions.

    Http://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?action=select&recall_number=D-0313-2015&w=12312014&lang=eng
    31 Dec 2014
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search